Sun Pharma Advanced Research Company (SPARC) has received Orphan Drug Designation from US Food and Drug Administration (USFDA) for Phenobarbital for the treatment of patients with neonatal seizures. The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in the United States.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.